« Return to News | Drug Sponsors

Pfizer to invest $200 million in Irish facility

Tuesday, September 20, 2011 01:33 PM

Pfizer has announced that it is to invest $200 million at its Grange Castle biotechnology manufacturing facility in Clondalkin, Co Dublin, according to PharmaTimes.

The investment will enable the drugs giant to introduce two new processing suites to the site and expand current production and product testing capabilities. Grange Castle is already one of the largest biotech manufacturing facilities in the world and currently produces two blockbusters - the pneumococcal disease vaccine Prevnar and the arthritis and psoriasis therapy Enbrel. The site currently employs 1,100 full-time staff.

Pfizer's chief financial officer, Frank D’Amelio, noted that with pharmaceutical and chemical products accounting for over 50% of Irish exports "and a long history in pharmaceutical excellence, Ireland is a prime location for this major investment.” He added that the Grange Castle project is "a strategic initiative that will allow us to further align and strengthen our manufacturing and supply network.”

The news was announced by Irish Taoiseach (prime minister) Enda Kenny, who noted that Pfizer has made "a tremendous contribution to Ireland’s life sciences industry since it first established here in 1969 and this investment is a further demonstration of the company’s continuous commitment" to the country.

Pfizer has some 4,300 staff in Ireland across eight locations based in Cork, Dublin, Kildare and Limerick. Total investment by the company in the country exceeds $7 billion.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.